CASP3 and familial dilated cardiomyopathy: To exemplify this, the POSEIDON-DCM trial found that allogeneic MSCs reduced serum TNF-α, while Mohamed et al. [49] reported reduced ventricular Caspase-3 protein following treatment [12].